PBS Expansion Improves Access to Key Kidney Disease Medication
04 Nov 2025
The change is expected to benefit around 65,000 Australians, easing the financial burden for patients who previously paid up to $670 per year for treatment.
Empagliflozin, first listed on the PBS in 2024, is now available to more people with chronic kidney disease, improving access to affordable and effective care.
For patient Peter Brown, who was diagnosed with both heart failure and chronic kidney disease, the expansion offers relief.
‘Because we’re on the pension, all the cost of the drugs does add up,’ he said. ‘For my health and for my wallet, I think this’ll be a good thing.’
With 2.7 million Australians showing signs of kidney disease — around 14.2% of adults, up from 10.8% a decade ago — the expansion comes at a crucial time.
Kidney Health Australia CEO Chris Forbes said the decision marks a “really important day” for patients, particularly those who are most vulnerable.
‘Having government support through the PBS gives people a better chance to see their doctor, get a kidney health check, and prevent serious kidney failure,’ he said.
Source: Department of Health and Aged Care / Kidney Health Australia / ABC News
